Biotech Insights: Future of GLP-1s, AI's Impact, and Tariffs

Citi Research's Anne Malone and Geoff Meacham discuss the future of GLP-1s, the impact of AI on biotech, and potential effects of tariffs. Malone, head of North America Equity Research, and Meacham, U.S. pharma and biotech research analyst, provide insights on the biotech industry.

UBS has revised its global GLP-1 sales forecast for 2030, slashing it from over $150 billion to $130 billion UBS slashes global GLP-1 sales estimate for 2030 on softer outlook^[1]. The downgrade is attributed to weaker-than-expected data from next-generation assets and compounded product disruptions in the US market. Despite the adjustment, UBS maintains that the GLP-1 and incretin market is one of the most exciting growth drivers in global pharma, projecting a 19% sales CAGR between 2024 and 2030. The obesity treatment segment is expected to see the largest expansion, growing from 4.4 million patients in 2024 to 34 million by 2030.

TNF Pharmaceuticals, Inc. has announced a collaboration with Renova Health to explore the effects of its lead candidate, isomyosamine (MYMD-1), on GLP-1-induced sarcopenia and frailty. The fully funded study will evaluate TNF-α levels in patients receiving GLP-1 agonists Wegovy or Ozempic who show signs of increased inflammation associated with sarcopenia TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs^[2]. This trial aims to address a significant issue in GLP-1 therapies, as up to 40% of the total weight lost by GLP-1 patients is lean body mass, including skeletal muscle mass.

Citi Research's Anne Malone and Geoff Meacham recently discussed the future of GLP-1s, the impact of AI on biotech, and potential effects of tariffs. Malone, head of North America Equity Research, and Meacham, U.S. pharma and biotech research analyst, provided insights into the biotech industry's prospects, including the role of AI in drug discovery and development. They also touched on the potential challenges posed by tariffs and how they might impact the industry.